Goldman Sachs
PAND

Goldman Sachs’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Goldman Sachs’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-796,286
Closed -$47.8M – 6833
2021
Q1 		$47.8M Buy
796,286
+770,049
+2,935% +$27.9M 0.01% 1202
2020
Q4 		$390K Buy
26,237
+7,744
+42% +$108K ﹤0.01% 4757
2020
Q3 		$212K Buy
+18,493
New +$316K ﹤0.01% 4888

Goldman Sachs's PAND Position: Q2 2021 in Review

Goldman Sachs sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 796,286 shares — an estimated $47.8M sold.

Goldman Sachs first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $47.8M in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • Goldman Sachs reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Goldman Sachs sold 796,286 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $47.8M.
  • Goldman Sachs first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Goldman Sachs's Pandion Therapeutics Inc. Common Stock position peaked at $47.8M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.